SlideShare a Scribd company logo
1 of 6
Download to read offline
SUPPLEMENTARY DATA
Supplementary Table 1. General characteristics of Type 2 diabetes subjects by obesity status
NON-OBESE

OBESE

Controls

Cases

Controls

Cases

692

643

298

384

42.1%

42.1%

33.9%

25% *†

54(49-63)

55(46-63) *

52(48-59)

51(42-59.5) *†

-

46(36-53)

-

45(38-52)

BMI (kg/m2)

26.2(24.527.7)

26.8(24.7-28.4)
*

32.6(31.1-34.5)

32.9(31.4-36.1) *†

Waist circumference (cm)

89.4(84-94)

94.1(88-101) *

103(97-110)

109(103.5-116.5)
*†

120(110-130)

129(119-140) *

126(118-140)

130(120-145.5) *†

Diastolic Blood Pressure
(mmHg)

80(70-84)

80(70-90) *

82(76.5-90)

86(80-90.5) *†

Glucose (mg/dL)

87(82-93)

226(148-318) *

Total Cholesterol (mg/dL)

213(189-241)

198(174-238) *

210(187-241.5)

209.5(178-236.5) *

Triglycerides (mg/dL)

153(112-226)

224(152-351) *

183(138.5257.5)

246(167-390) *†

HDL (mg/dL)

44(38-53)

39(32-45) *

41(35-49)

37.5(30-44) *

LDL (mg/dL)

134(114-159)

111(85-138) *

129(111-151)

112.5(87-139) *

Individuals (n)
Male (%)
Age (years)
Age at diagnosis (years)

Systolic Blood Pressure (mmHg)

92(85-97)

213.5(147-306) *

Median and percentiles 25 and 75 of baseline characteristics are shown. Statistically significant
observations are bold- faced. *P< 0.05 comparisons between type 2 diabetes cases and controls.
†P< 0.05 comparisons between non obese and obese type 2 diabetes cases.

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1
SUPPLEMENTARY DATA
Supplementary Table 2. Allele frequency distribution of 21 SNPs studied in Mexican Mestizos population and the comparison with
Europeans
Nearest Gene

Chr

SNP

RA

KCNJ11
PPARG
TCF7L2
SLC30A8

11
3
10
8

HHEX

10

CDKN2A/2B
CDKAL1
IGF2BP2
ARHGEF11
JAZF1
CDC123/ CAMK1D
FTO
TSPAN8/ LGR5
KCNQ1
ADAMTS9
NOTCH2
NXPH1
RORA
UBQLNL
RALGPS2

9
6
3
1
7
10
16
12
11
3
1
7
15
11
1

rs5219
rs1801282
rs7903146
rs13266634
rs1111875
rs7923837
rs10811661
rs7754840
rs4402960
rs945508
rs864745
rs12779790
rs8050136
rs7961581
rs2237892
rs4607103
rs10923931
rs757705
rs7164773
rs979752
rs2773080

T
C
T
C
C
G
T
C
T
A
T
G
A
C
C
C
T
G
T
C
A

Controls
0.373
0.868
0.163
0.729
0.623
0.455
0.877
0.285
0.191
0.252
0.660
0.161
0.200
0.125
0.663
0.697
0.078
0.654
0.625
0.854
0.197

Total
Cases
0.396
0.877
0.172
0.770
0.626
0.485
0.911
0.313
0.213
0.233
0.679
0.197
0.194
0.132
0.720
0.710
0.081
0.684
0.641
0.850
0.193

Early
Onset
0.399
0.876
0.180
0.788
0.626
0.458
0.913
0.326
0.199
0.225
0.692
0.213
0.192
0.132
0.723
0.720
0.083
0.694
0.642
0.853
0.181

Risk Allele frequency
Non obese
Late
Onset
Controls Cases
0.393
0.374
0.408
0.877
0.866
0.875
0.163
0.170
0.171
0.752
0.726
0.769
0.626
0.620
0.621
0.512
0.452
0.500
0.909
0.880
0.912
0.300
0.275
0.326
0.227
0.197
0.213
0.241
0.259
0.217
0.666
0.661
0.687
0.182
0.161
0.202
0.197
0.190
0.182
0.132
0.133
0.139
0.717
0.669
0.721
0.701
0.688
0.706
0.079
0.081
0.079
0.674
0.658
0.689
0.639
0.627
0.647
0.847
0.848
0.855
0.205
0.199
0.196

Obese
European*
Controls Cases Controls Cases
0.371
0.375 0.464† 0.489‡
0.872
0.879
0.823
0.848
0.149
0.172
0.181
0.227‡
0.736
0.770 0.609† 0.649‡
0.628
0.635 0.522† 0.546‡
0.464
0.461 0.597† 0.622‡
0.871
0.909 0.850† 0.872‡
0.307
0.293 0.360† 0.387‡
0.177
0.213 0.304† 0.341‡
0.236
0.260 0.460†
0.660
0.666 0.501†
0.161
0.188
0.183
0.223
0.217 0.381† 0.406‡
0.108
0.120 0.269†
0.650
0.719 0.930†
0.715
0.718 0.761†
0.073
0.084 0.106†
0.643
0.674
0.621
0.630
0.869
0.840
0.194
0.188
-

Chr, Chromosome; RA, Risk Allele; defined as previously reported associated to T2D risk in other populations. * Risk allele frequencies
reported in European population. † P<0.05 comparisons of risk allele frequencies between Mexican controls and European controls. ‡
Statistically significant differences between Mexican-Mestizo and European population type 2 diabetes cases.

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1
SUPPLEMENTARY DATA
Supplementary Table 3. Comparison of the effect sizes in Mexicans vs. European populations.

OR (95% CI)

p-value

OR (95% CI)

Heterogeneity
Test

TCF7L2

1.39(1.04-1.85)

0.024

1.37(1.31-1.43)

0.92

rs13266634

SLC30A8

1.22(1.05-1.41)

0.009

1.12(1.07-1.16)

0.26

rs7923837

HHEX

1.21(1.02-1.44)

0.025

1.22(1.01-1.43)

0.95

rs10811661

CDKN2A/2B

1.42(1.15-1.75)

0.001

1.20(1.14-1.25)

0.12

rs7754840

CDKAL1

1.25(1.06-1.49)

0.009

1.12(1.08-1.16)

0.23

rs4402960

IGF2BP2

1.24 (1.01-1.53)

0.042

1.14(1.11-1.18)

0.44

1.24(1.05-1.47)

0.013

1.11(1.07-1.14)

0.21

1.36(1.13-1.64)

0.001

1.42 (1.34–1.49)
1.43(1.34-1.52)*

0.62
0.66

SNP
rs7903146

Mexican Mestizos

Nearest Gene

rs12779790 CDC123/CAMK1D
rs2237892

KCNQ1

Reported in Europeans

Odds ratios in Mexican and European populations are shown. * Odds ratio reported in Asians.
Supplementary Table 4. Ancestry Informative Markers (AIMs) used in the study.
dbSNP RS ID Number
rs2817611
rs6684063
rs1934393
rs3768176
rs3828121
rs3806218
rs2592888
rs4657449
rs7535375
rs1073319
rs1470524
rs842634
rs10515919
rs4852696
rs3860446
rs1036543
rs2711070
rs868179
rs10497705
rs1517634
rs10498255
rs304051
rs1498991
rs9310888

Chromosome
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3

Physical
Location
11322709
30201812
48578535
56937923
81844793
144518860
156802365
162652658
232954308
29414989
45104050
61065756
75515133
83126181
104110751
133886983
159705078
177752041
190694557
224386024
231814769
4553306
20875097
29261727

Delta_Af_Eu
0.675
0.611
0.620
0.044
0.131
0.608
0.674
0.012
0.603
0.107
0.563
0.234
0.020
0.655
0.615
0.726
0.325
0.627
0.120
0.000
0.560
0.202
0.032
0.592

Delta_Af_NA
0.689
0.056
0.078
0.739
0.700
0.763
0.912
0.650
0.689
0.750
0.311
0.739
0.694
0.450
0.028
0.017
0.828
0.700
0.749
0.833
0.717
0.750
0.694
0.667

Delta_Eu_NA
0.014
0.667
0.542
0.695
0.569
0.155
0.238
0.662
0.086
0.643
0.252
0.505
0.714
0.205
0.643
0.743
0.502
0.073
0.629
0.833
0.157
0.548
0.726
0.075

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1
SUPPLEMENTARY DATA
rs10510791
rs1395771
rs1919550
rs2035573
rs1984473
rs6804094
rs1398829
rs719776
rs10517518
rs9307613
rs10519979
rs10520440
rs257748
rs1353251
rs9292118
rs6883095
rs153898
rs1990745
rs10515535
rs1477277
rs6911727
rs10484578
rs993314
rs9320808
rs6569792
rs9295316
rs10486576
rs10248051
rs10214949
rs10488172
rs802524
rs9325872
rs7463344
rs4130405
rs1898280
rs4733652
rs2840290
rs4013967
rs10491654
rs10508349
rs2785279
rs4934436
rs1397618
rs2595456
rs948360
rs10501474
rs567992
rs879780

3
3
3
3
3
3
4
4
4
4
4
4
5
5
5
5
5
5
5
5
6
6
6
6
6
6
7
7
7
7
7
8
8
8
8
8
9
9
9
10
10
10
10
11
11
11
11
11

57251433
97784481
122685074
132534415
157132197
188378883
21774158
33583840
61798796
130816225
150212578
181494895
15872353
35902708
55916081
79975120
94262695
103458138
143544652
180784684
9061397
35293174
73434170
121635172
132675321
158476352
27861415
50861102
78660644
132751390
145343383
20490544
33921195
99377358
116031043
129801116
16723957
72354189
97519365
8302970
33713882
90447897
120497262
6849072
65882085
80126955
105800114
129545756

0.484
0.632
0.004
0.317
0.575
0.318
0.754
0.774
0.087
0.681
0.285
0.214
0.425
0.175
0.657
0.313
0.655
0.119
0.714
0.655
0.337
0.569
0.733
0.766
0.567
0.068
0.044
0.750
0.564
0.187
0.651
0.623
0.639
0.190
0.651
0.155
0.593
0.596
0.214
0.044
0.562
0.242
0.658
0.218
0.724
0.587
0.155
0.619

0.839
0.090
0.806
0.839
0.911
0.839
0.778
0.750
0.811
0.740
0.800
0.833
0.161
0.706
0.790
0.828
0.050
0.767
0.867
0.700
0.861
0.878
0.200
0.106
0.689
0.837
0.744
0.117
0.685
0.772
0.689
0.056
0.639
0.800
0.056
0.817
0.039
0.941
0.400
0.711
0.757
0.272
0.706
0.306
0.750
0.744
0.667
0.667

0.354
0.543
0.810
0.521
0.336
0.521
0.024
0.024
0.724
0.058
0.515
0.619
0.586
0.531
0.133
0.514
0.705
0.648
0.152
0.045
0.524
0.308
0.533
0.871
0.121
0.769
0.700
0.633
0.121
0.586
0.038
0.679
0.000
0.610
0.595
0.662
0.632
0.345
0.614
0.755
0.195
0.514
0.048
0.524
0.026
0.157
0.512
0.048

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1
SUPPLEMENTARY DATA
rs4625554
rs4762106
rs10506816
rs249847
rs4076700
rs4034627
rs2585901
rs10507688
rs5000507
rs10492585
rs9323178
rs1451928
rs2296274
rs10131076
rs9302185
rs10520678
rs30125
rs1004704
rs10500505
rs4130513
rs10491097
rs1990743
rs2253624
rs1013459
rs2042762
rs12953952
rs888861
rs708915
rs2208139
rs354747
rs2829454
rs138022

12
12
12
12
12
12
13
13
13
13
14
14
14
14
15
15
16
16
16
16
17
17
17
18
18
18
19
20
20
20
21
22

4286565
64304740
78427325
97370184
115795273
126750571
19218271
61204229
79886955
103084177
21103774
46330779
59907219
78764426
52670920
86667051
14321100
48315382
64718164
78238277
19523240
64494057
70329204
11690534
33529609
65886896
40073692
8395667
38594383
59598070
25194942
38856075

0.131
0.710
0.861
0.408
0.627
0.734
0.089
0.167
0.574
0.840
0.276
0.004
0.632
0.623
0.685
0.578
0.590
0.187
0.159
0.639
0.592
0.005
0.824
0.667
0.000
0.788
0.738
0.635
0.167
0.560
0.218
0.571

0.700
0.139
0.761
0.911
0.694
0.748
0.698
0.733
0.861
0.900
0.790
0.661
0.849
0.694
0.842
0.846
0.539
0.839
0.744
0.530
0.078
0.572
0.824
0.733
0.733
0.828
0.900
0.002
0.800
0.683
0.878
0.800

0.569
0.571
0.100
0.503
0.067
0.014
0.787
0.567
0.288
0.060
0.514
0.657
0.217
0.071
0.157
0.268
0.051
0.652
0.586
0.109
0.514
0.567
0.000
0.067
0.733
0.040
0.162
0.633
0.633
0.124
0.660
0.229

Delta_Af_Eu - Difference in allele frequency between Africans and Europeans; Delta_Af_NA Difference in allele frequency between Africans and Native Americans; Delta_Eu_NA - Difference in
allele frequency between Europeans and Native Americans
.

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1
SUPPLEMENTARY DATA
Supplementary Table 5. Allele frequency distribution of the 3 SNPs not considered in the association analysis.
Nearest Gene

Chr

SNP

RA

CDKAL1
IGF2BP2
THADA

6
3
2

rs10484634†
rs1470579‡
rs7578597†

T
C
T

Controls
0.974
0.190
0.959

Total
Cases
0.980
0.213
0.964

Early
Onset
0.978
0.203
0.971

Risk Allele frequency
Non obese
Obese
European*
Late
Onset
Controls Cases Controls Cases Controls Cases
0.980
0.979
0.980
0.964
0.980
0.222
0.192
0.213
0.185
0.213
0.30
0.32
0.957
0.958
0.963
0.961
0.965
0.90
-

Chr, Chromosome; RA, Risk Allele; defined as previously reported associated to T2D risk in other populations. * Risk allele frequencies
reported in European population. †SNPs with a minor allele frequency < 0.05. ‡SNP is not in Hardy–Weinberg equilibrium in control group
(p=0.002).

©2012 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0550/-/DC1

More Related Content

What's hot

Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?My Healthy Waist
 
Ryden 9 16
Ryden 9 16Ryden 9 16
Ryden 9 16fshequin
 
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...National Osteoporosis Society
 
Logistic regression1
Logistic regression1Logistic regression1
Logistic regression1LoiLe36
 
Cm2 4. association of the hind iii and s447x in t2d
Cm2 4. association of the hind iii and s447x in t2dCm2 4. association of the hind iii and s447x in t2d
Cm2 4. association of the hind iii and s447x in t2dGibran Fadl
 
Nsaids and cvs risk
Nsaids and cvs riskNsaids and cvs risk
Nsaids and cvs riskRichin Koshy
 
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...My Healthy Waist
 
Presentation on diabetes by Dr Kalpana Namdeo Lahade
Presentation on diabetes by Dr Kalpana Namdeo LahadePresentation on diabetes by Dr Kalpana Namdeo Lahade
Presentation on diabetes by Dr Kalpana Namdeo LahadeDR KALPANA LAHADE
 
Evaluating cardiometabolic risk
Evaluating cardiometabolic riskEvaluating cardiometabolic risk
Evaluating cardiometabolic riskMy Healthy Waist
 

What's hot (9)

Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
Ryden 9 16
Ryden 9 16Ryden 9 16
Ryden 9 16
 
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amon...
 
Logistic regression1
Logistic regression1Logistic regression1
Logistic regression1
 
Cm2 4. association of the hind iii and s447x in t2d
Cm2 4. association of the hind iii and s447x in t2dCm2 4. association of the hind iii and s447x in t2d
Cm2 4. association of the hind iii and s447x in t2d
 
Nsaids and cvs risk
Nsaids and cvs riskNsaids and cvs risk
Nsaids and cvs risk
 
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...
Abdominal obesity, intra-abdominal adiposity and related cardiometabolic risk...
 
Presentation on diabetes by Dr Kalpana Namdeo Lahade
Presentation on diabetes by Dr Kalpana Namdeo LahadePresentation on diabetes by Dr Kalpana Namdeo Lahade
Presentation on diabetes by Dr Kalpana Namdeo Lahade
 
Evaluating cardiometabolic risk
Evaluating cardiometabolic riskEvaluating cardiometabolic risk
Evaluating cardiometabolic risk
 

Viewers also liked

Sju高溫爐講義
Sju高溫爐講義Sju高溫爐講義
Sju高溫爐講義houhsiting
 
Comp testo
Comp testoComp testo
Comp testoimartini
 
Solución de problemas
Solución de problemasSolución de problemas
Solución de problemasiturracarla
 
Workshop brief boswell 130903101823-
Workshop brief boswell 130903101823-Workshop brief boswell 130903101823-
Workshop brief boswell 130903101823-alboss23
 
15分でわかるTPP-TPPは日本を豊かにできるのか-
15分でわかるTPP-TPPは日本を豊かにできるのか-15分でわかるTPP-TPPは日本を豊かにできるのか-
15分でわかるTPP-TPPは日本を豊かにできるのか-Yasuyuki Todo
 
PHP Orientado a Objetos - 1a Parte
PHP Orientado a Objetos - 1a PartePHP Orientado a Objetos - 1a Parte
PHP Orientado a Objetos - 1a ParteJonata Weber
 
Prova presentacio images
Prova presentacio imagesProva presentacio images
Prova presentacio imagescfapalaudemar
 
Lettre electronique dec janv_2014 2015
Lettre electronique dec janv_2014 2015Lettre electronique dec janv_2014 2015
Lettre electronique dec janv_2014 2015Pierre AVRIL
 
un evento paranormal ?? en Montecristi (Ecuador)
un evento paranormal ?? en Montecristi (Ecuador)un evento paranormal ?? en Montecristi (Ecuador)
un evento paranormal ?? en Montecristi (Ecuador)Jaime Zapata Salazar
 
Original_draft_file
Original_draft_fileOriginal_draft_file
Original_draft_fileSS Free
 
ProLife NWT Business Presentation Team Excel
ProLife NWT Business Presentation Team ExcelProLife NWT Business Presentation Team Excel
ProLife NWT Business Presentation Team ExcelTeamExcel
 
Trabajo web biologia belen, maria y carmen
Trabajo web biologia belen, maria y carmenTrabajo web biologia belen, maria y carmen
Trabajo web biologia belen, maria y carmenmariamolina98
 
Consejos de un padre a un hijo para vivir feliz
Consejos de un padre a un hijo para vivir felizConsejos de un padre a un hijo para vivir feliz
Consejos de un padre a un hijo para vivir felizLuis Rubio
 
Prestige8 new
Prestige8 newPrestige8 new
Prestige8 newprestige8
 
PRUEBA DE INFORMATICA APLICADA
PRUEBA DE INFORMATICA APLICADA PRUEBA DE INFORMATICA APLICADA
PRUEBA DE INFORMATICA APLICADA 1516Maria
 

Viewers also liked (19)

Sju高溫爐講義
Sju高溫爐講義Sju高溫爐講義
Sju高溫爐講義
 
Comp testo
Comp testoComp testo
Comp testo
 
Halloween 2013
Halloween 2013Halloween 2013
Halloween 2013
 
Prueba de informacion general de revisión
Prueba de informacion general de revisiónPrueba de informacion general de revisión
Prueba de informacion general de revisión
 
Solución de problemas
Solución de problemasSolución de problemas
Solución de problemas
 
Workshop brief boswell 130903101823-
Workshop brief boswell 130903101823-Workshop brief boswell 130903101823-
Workshop brief boswell 130903101823-
 
15分でわかるTPP-TPPは日本を豊かにできるのか-
15分でわかるTPP-TPPは日本を豊かにできるのか-15分でわかるTPP-TPPは日本を豊かにできるのか-
15分でわかるTPP-TPPは日本を豊かにできるのか-
 
PHP Orientado a Objetos - 1a Parte
PHP Orientado a Objetos - 1a PartePHP Orientado a Objetos - 1a Parte
PHP Orientado a Objetos - 1a Parte
 
Prova presentacio images
Prova presentacio imagesProva presentacio images
Prova presentacio images
 
Lettre electronique dec janv_2014 2015
Lettre electronique dec janv_2014 2015Lettre electronique dec janv_2014 2015
Lettre electronique dec janv_2014 2015
 
un evento paranormal ?? en Montecristi (Ecuador)
un evento paranormal ?? en Montecristi (Ecuador)un evento paranormal ?? en Montecristi (Ecuador)
un evento paranormal ?? en Montecristi (Ecuador)
 
Original_draft_file
Original_draft_fileOriginal_draft_file
Original_draft_file
 
ProLife NWT Business Presentation Team Excel
ProLife NWT Business Presentation Team ExcelProLife NWT Business Presentation Team Excel
ProLife NWT Business Presentation Team Excel
 
20151113 parlamentaria
20151113 parlamentaria20151113 parlamentaria
20151113 parlamentaria
 
Trabajo web biologia belen, maria y carmen
Trabajo web biologia belen, maria y carmenTrabajo web biologia belen, maria y carmen
Trabajo web biologia belen, maria y carmen
 
Consejos de un padre a un hijo para vivir feliz
Consejos de un padre a un hijo para vivir felizConsejos de un padre a un hijo para vivir feliz
Consejos de un padre a un hijo para vivir feliz
 
Prestige8 new
Prestige8 newPrestige8 new
Prestige8 new
 
CONVERSATORIO: “Complejo Quinua-Camélidos- Medio Ambiente” Oruro, domingo 28 ...
CONVERSATORIO: “Complejo Quinua-Camélidos- Medio Ambiente” Oruro, domingo 28 ...CONVERSATORIO: “Complejo Quinua-Camélidos- Medio Ambiente” Oruro, domingo 28 ...
CONVERSATORIO: “Complejo Quinua-Camélidos- Medio Ambiente” Oruro, domingo 28 ...
 
PRUEBA DE INFORMATICA APLICADA
PRUEBA DE INFORMATICA APLICADA PRUEBA DE INFORMATICA APLICADA
PRUEBA DE INFORMATICA APLICADA
 

Similar to Supplementarydata

Metabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspectiveMetabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspectiveMy Healthy Waist
 
Abbotsford feb 26 2014
Abbotsford feb 26 2014Abbotsford feb 26 2014
Abbotsford feb 26 2014Ihsaan Peer
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseChristos Argyropoulos
 
Does combination therapy with statins and fibrates prevent cardiovascular dis...
Does combination therapy with statinsand fibrates prevent cardiovascular dis...Does combination therapy with statinsand fibrates prevent cardiovascular dis...
Does combination therapy with statins and fibrates prevent cardiovascular dis...filtheo1
 
Ueda2016 metabolic syndrome in different population,which one is appropriate ...
Ueda2016 metabolic syndrome in different population,which one is appropriate ...Ueda2016 metabolic syndrome in different population,which one is appropriate ...
Ueda2016 metabolic syndrome in different population,which one is appropriate ...ueda2015
 
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...Mikołaj Kamiński
 
barrett's esophagus in SOT patients [1440].pptx
barrett's esophagus in SOT patients [1440].pptxbarrett's esophagus in SOT patients [1440].pptx
barrett's esophagus in SOT patients [1440].pptxdrpatel5794
 
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Dr. Jair García-Guerrero
 
Hindoestanen
HindoestanenHindoestanen
HindoestanenspankvdA
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskPrimary Care Diabetes Europe
 
new_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptnew_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptMsccMohamed
 
Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedDr. Lin
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiologydavid7s
 
Nonalcoholic fatty liver disease and carotid atherosclerosis in children
Nonalcoholic fatty liver disease and carotid atherosclerosis in childrenNonalcoholic fatty liver disease and carotid atherosclerosis in children
Nonalcoholic fatty liver disease and carotid atherosclerosis in childrenSHAPE Society
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetesPeninsulaEndocrine
 
3 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 20153 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 2015NHS Improving Quality
 
ueda2012 reducing risk of cardiovascular diseases-d.nabil
ueda2012 reducing risk of cardiovascular diseases-d.nabilueda2012 reducing risk of cardiovascular diseases-d.nabil
ueda2012 reducing risk of cardiovascular diseases-d.nabilueda2015
 

Similar to Supplementarydata (20)

Metabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspectiveMetabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspective
 
Abbotsford feb 26 2014
Abbotsford feb 26 2014Abbotsford feb 26 2014
Abbotsford feb 26 2014
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
 
Does combination therapy with statins and fibrates prevent cardiovascular dis...
Does combination therapy with statinsand fibrates prevent cardiovascular dis...Does combination therapy with statinsand fibrates prevent cardiovascular dis...
Does combination therapy with statins and fibrates prevent cardiovascular dis...
 
Lupus nephritis
Lupus nephritisLupus nephritis
Lupus nephritis
 
Ueda2016 metabolic syndrome in different population,which one is appropriate ...
Ueda2016 metabolic syndrome in different population,which one is appropriate ...Ueda2016 metabolic syndrome in different population,which one is appropriate ...
Ueda2016 metabolic syndrome in different population,which one is appropriate ...
 
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...
Insulin resistance in adults with Type 1 Diabetes is associated with lower wi...
 
barrett's esophagus in SOT patients [1440].pptx
barrett's esophagus in SOT patients [1440].pptxbarrett's esophagus in SOT patients [1440].pptx
barrett's esophagus in SOT patients [1440].pptx
 
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
 
Hindoestanen
HindoestanenHindoestanen
Hindoestanen
 
SGLT2i
SGLT2iSGLT2i
SGLT2i
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease risk
 
new_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptnew_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.ppt
 
Workshop rpt-5-qualidiab
Workshop rpt-5-qualidiabWorkshop rpt-5-qualidiab
Workshop rpt-5-qualidiab
 
Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approved
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
 
Nonalcoholic fatty liver disease and carotid atherosclerosis in children
Nonalcoholic fatty liver disease and carotid atherosclerosis in childrenNonalcoholic fatty liver disease and carotid atherosclerosis in children
Nonalcoholic fatty liver disease and carotid atherosclerosis in children
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetes
 
3 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 20153 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 2015
 
ueda2012 reducing risk of cardiovascular diseases-d.nabil
ueda2012 reducing risk of cardiovascular diseases-d.nabilueda2012 reducing risk of cardiovascular diseases-d.nabil
ueda2012 reducing risk of cardiovascular diseases-d.nabil
 

Recently uploaded

How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfSrushith Repakula
 
Tales from a Passkey Provider Progress from Awareness to Implementation.pptx
Tales from a Passkey Provider  Progress from Awareness to Implementation.pptxTales from a Passkey Provider  Progress from Awareness to Implementation.pptx
Tales from a Passkey Provider Progress from Awareness to Implementation.pptxFIDO Alliance
 
ADP Passwordless Journey Case Study.pptx
ADP Passwordless Journey Case Study.pptxADP Passwordless Journey Case Study.pptx
ADP Passwordless Journey Case Study.pptxFIDO Alliance
 
Design and Development of a Provenance Capture Platform for Data Science
Design and Development of a Provenance Capture Platform for Data ScienceDesign and Development of a Provenance Capture Platform for Data Science
Design and Development of a Provenance Capture Platform for Data SciencePaolo Missier
 
CORS (Kitworks Team Study 양다윗 발표자료 240510)
CORS (Kitworks Team Study 양다윗 발표자료 240510)CORS (Kitworks Team Study 양다윗 발표자료 240510)
CORS (Kitworks Team Study 양다윗 발표자료 240510)Wonjun Hwang
 
Top 10 CodeIgniter Development Companies
Top 10 CodeIgniter Development CompaniesTop 10 CodeIgniter Development Companies
Top 10 CodeIgniter Development CompaniesTopCSSGallery
 
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...panagenda
 
ChatGPT and Beyond - Elevating DevOps Productivity
ChatGPT and Beyond - Elevating DevOps ProductivityChatGPT and Beyond - Elevating DevOps Productivity
ChatGPT and Beyond - Elevating DevOps ProductivityVictorSzoltysek
 
ERP Contender Series: Acumatica vs. Sage Intacct
ERP Contender Series: Acumatica vs. Sage IntacctERP Contender Series: Acumatica vs. Sage Intacct
ERP Contender Series: Acumatica vs. Sage IntacctBrainSell Technologies
 
How to Check CNIC Information Online with Pakdata cf
How to Check CNIC Information Online with Pakdata cfHow to Check CNIC Information Online with Pakdata cf
How to Check CNIC Information Online with Pakdata cfdanishmna97
 
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdf
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdfFrisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdf
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdfAnubhavMangla3
 
2024 May Patch Tuesday
2024 May Patch Tuesday2024 May Patch Tuesday
2024 May Patch TuesdayIvanti
 
AI in Action: Real World Use Cases by Anitaraj
AI in Action: Real World Use Cases by AnitarajAI in Action: Real World Use Cases by Anitaraj
AI in Action: Real World Use Cases by AnitarajAnitaRaj43
 
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...TrustArc
 
WebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceWebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceSamy Fodil
 
Intro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptxIntro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptxFIDO Alliance
 
State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!Memoori
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdfMuhammad Subhan
 
UiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewUiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewDianaGray10
 

Recently uploaded (20)

How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 
Tales from a Passkey Provider Progress from Awareness to Implementation.pptx
Tales from a Passkey Provider  Progress from Awareness to Implementation.pptxTales from a Passkey Provider  Progress from Awareness to Implementation.pptx
Tales from a Passkey Provider Progress from Awareness to Implementation.pptx
 
ADP Passwordless Journey Case Study.pptx
ADP Passwordless Journey Case Study.pptxADP Passwordless Journey Case Study.pptx
ADP Passwordless Journey Case Study.pptx
 
Design and Development of a Provenance Capture Platform for Data Science
Design and Development of a Provenance Capture Platform for Data ScienceDesign and Development of a Provenance Capture Platform for Data Science
Design and Development of a Provenance Capture Platform for Data Science
 
CORS (Kitworks Team Study 양다윗 발표자료 240510)
CORS (Kitworks Team Study 양다윗 발표자료 240510)CORS (Kitworks Team Study 양다윗 발표자료 240510)
CORS (Kitworks Team Study 양다윗 발표자료 240510)
 
Overview of Hyperledger Foundation
Overview of Hyperledger FoundationOverview of Hyperledger Foundation
Overview of Hyperledger Foundation
 
Top 10 CodeIgniter Development Companies
Top 10 CodeIgniter Development CompaniesTop 10 CodeIgniter Development Companies
Top 10 CodeIgniter Development Companies
 
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
 
ChatGPT and Beyond - Elevating DevOps Productivity
ChatGPT and Beyond - Elevating DevOps ProductivityChatGPT and Beyond - Elevating DevOps Productivity
ChatGPT and Beyond - Elevating DevOps Productivity
 
ERP Contender Series: Acumatica vs. Sage Intacct
ERP Contender Series: Acumatica vs. Sage IntacctERP Contender Series: Acumatica vs. Sage Intacct
ERP Contender Series: Acumatica vs. Sage Intacct
 
How to Check CNIC Information Online with Pakdata cf
How to Check CNIC Information Online with Pakdata cfHow to Check CNIC Information Online with Pakdata cf
How to Check CNIC Information Online with Pakdata cf
 
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdf
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdfFrisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdf
Frisco Automating Purchase Orders with MuleSoft IDP- May 10th, 2024.pptx.pdf
 
2024 May Patch Tuesday
2024 May Patch Tuesday2024 May Patch Tuesday
2024 May Patch Tuesday
 
AI in Action: Real World Use Cases by Anitaraj
AI in Action: Real World Use Cases by AnitarajAI in Action: Real World Use Cases by Anitaraj
AI in Action: Real World Use Cases by Anitaraj
 
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
 
WebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceWebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM Performance
 
Intro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptxIntro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptx
 
State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
 
UiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overviewUiPath manufacturing technology benefits and AI overview
UiPath manufacturing technology benefits and AI overview
 

Supplementarydata